4D Molecular Therapeutics Inc (FDMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $689.52M
Last updated: Nov 17, 2026 at 11:06 AM ET
4D Molecular Therapeutics Inc (FDMT) Competitors
The companies most similar to 4D Molecular Therapeutics are Design Therapeutics (DSGN), DBV Technologies (DBVT) and Taysha Gene Therapies (TSHA). By market cap, 4D Molecular Therapeutics ranks 6th of the 13 companies on this page; Taysha Gene Therapies (TSHA) is the largest at $1.34B.
Peer Comparison
FDMT's ROIC of -46.4% is below the peer median of -38.1%, and its revenue growth of 4506.0% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics (FDMT) | $689.52M | N/A | 8.5x | -208.6% | -46.4% | 4506.0% | 0.00% |
| Design Therapeutics Inc (DSGN) | $670.46M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Taysha Gene Therapies Inc (TSHA) | $1.34B | N/A | 300.6x | 0.0% | -32.8% | 171.3% | 0.00% |
| DiaMedica Therapeutics Inc (DMAC) | $474.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Alpha Tau Medical Ltd (DRTS) | $1.24B | N/A | N/A | 0.0% | -176.9% | 0.0% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Solid Biosciences LLC (SLDB) | $763.42M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Candel Therapeutics Inc (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Peer median | $676.86M | 95.1x | 8.3x | 0.0% | -38.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to 4D Molecular Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Design Therapeutics Inc (DSGN) | Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. | DSGN competitors |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Taysha Gene Therapies Inc (TSHA) | Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies... | TSHA competitors |
| DiaMedica Therapeutics Inc (DMAC) | DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. | DMAC competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Alpha Tau Medical Ltd (DRTS) | Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development... | DRTS competitors |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Solid Biosciences LLC (SLDB) | Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. | SLDB competitors |
| Candel Therapeutics Inc (CADL) | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform... | CADL competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. |
Frequently Asked Questions About FDMT
Who are 4D Molecular Therapeutics' main competitors?
The companies most similar to 4D Molecular Therapeutics include Design Therapeutics (DSGN), DBV Technologies (DBVT), Taysha Gene Therapies (TSHA), DiaMedica Therapeutics (DMAC) and Neurogene (NGNE), listed from the closest match.
Who is 4D Molecular Therapeutics' biggest competitor?
Taysha Gene Therapies (TSHA) is the largest of the similar companies at $1.34B; Design Therapeutics (DSGN) is the closest match by business profile, size, sector and industry.
How does FDMT stock compare with its competitors?
FDMT's P/S is 8.5x against a peer median of 8.3x; its net margin is -208.6% against a peer median of 0.0%.
Which of 4D Molecular Therapeutics' competitors pays a higher dividend?
4D Molecular Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is 4D Molecular Therapeutics bigger than its competitors?
No. 4D Molecular Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Taysha Gene Therapies (TSHA) at $1.34B.
FDMT pages: Overview, Earnings, Forecast, Financials, Competitors